

A Walkthrough of Recent COVID-19 Coding & Billing Updates

February 2021



Ardith Campbell

COC, CPC Manager, Product Content

New ICD-10-CM Codes

Effective January 1, 2021

ICD-10-CM Codes

Z86.16 Personal history of COVID-19

J12.82 Pneumonia due to coronavirus disease 2019

M35.81 Multisystem inflammatory syndrome

M35.89 Other specified systemic involvement of connective tissue

Z11.52 Encounter for screening for COVID-19

Z20.822 Contact with and (suspected) exposure to COVID-19

New CPT® & HCPCS Codes

By Effective Date, Outside of Annual Updates

November 10, 2020

87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B

M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring

Q0239 Injection, bamlanivimab-xxxx, 700 mg

November 21, 2020

**M0243 Intravenous infusion, casirivimab and imdevimab
includes infusion and post administration monitoring**

Q0243 Injection, casirivimab and imdevimab, 2400 mg

December 11, 2020

Pfizer-BioNTech Vaccine

91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose

0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose

December 18, 2020

Moderna Vaccine

91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

0011A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose

0012A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose

Effective Date is EUA Approval

AstraZeneca Vaccine

91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage, for intramuscular use

0021A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage; first dose

0022A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage; second dose

Effective Date is EUA Approval

Janssen COVID-19 Vaccine (Johnson & Johnson)

91303 Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage, for intramuscular use

0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage, single dose

COVID-19 Diagnosis Codes

Screening Versus Exposure

Screening Versus Exposure

(f) Screening for COVID-19

During the COVID-19 pandemic, a screening code is generally not appropriate. **Do not assign code Z11.52, Encounter for screening for COVID-19.** For encounters for COVID-19 testing, including preoperative testing, code as exposure to COVID-19 (guideline I.C.1.g.1.e).

Coding guidance will be updated as new information concerning any changes in the pandemic status becomes available.

Screening Versus Exposure, Cont

(e) Exposure to COVID-19

For asymptomatic individuals with actual or suspected exposure to COVID-19, assign code Z20.822, Contact with and (suspected) exposure to COVID-19.

For symptomatic individuals with actual or suspected exposure to COVID-19 and the infection has been ruled out, or test results are inconclusive or unknown, assign code Z20.822, Contact with and (suspected) exposure to COVID-19. See guideline I.C.21.c.1, Contact/Exposure, for additional guidance regarding the use of category Z20 codes.

If COVID-19 is confirmed, see guideline I.C.1.g.1.a.

1.C.1.g.1.a. Code only confirmed cases

COVID-19 Medication Treatments & Vaccines

Payer Policy in Play

Medications, Treatments, Vaccines

- CMS placed bamlanivimab and casirivimab/imdevimab infusions under the Medicare Vaccine Benefit
- Physician order is required
- Does not follow the infusion/injection hierarchy
- Medicare Advantage (MA) beneficiary claims for infusion go to original Medicare
- MA beneficiary claims for other treatments go to MA plan
- Contact Medicare Administrative Contractor (MAC)

Medications, Treatments, Vaccines, Cont

- **Claims submission – just send a line item with the administration whether infusion or vaccine**
- **Claim scrubber or payer has an edit?**
 - Pub. 100-04 Medicare Claims Processing Manual, Chap. 32 Billing Requirements for Special Services, Subsection 67.2 Institutional Billing for No Cost Items
 - Token charge of less than \$1.01, modifier(s)

Medications, Treatments, Vaccines, Cont

- Inpatient claims – bill the way you do for influenza vaccine
 - Use Type of Bill 012X INPATIENT HOSPITAL (MEDICARE PART B ONLY)
 - Date of service is discharge date
- “...During the COVID-19 public health emergency (PHE), Medicare will cover and pay for these infusions (when furnished consistent with their respective EUAs) the same way it covers and pays for COVID-19 vaccines....”

Medications, Treatments, Vaccines, Cont

- Reimbursement for infusion and post-administration monitoring \$309.600
- Vaccine Administration for 2-dose schedule
 - First dose \$16.940
 - Second dose \$28.390
 - Second dose rate higher to incentivize patients receiving second dose
- Vaccine for single-dose only \$28.390

Flexibilities Made Permanent

Calendar Year (CY) 2021 Final Rules

Flexibilities Made Permanent - OPPS

- **Subject to your state's regulations**
- **Now General Supervision**
 - Non-Surgical Extended Duration Therapeutic Services (NSDETS)
- **Pulmonary, Cardiac, and Intensive Cardiac Rehabilitation Services direct supervision through audio/video real-time communications discussed but not approved**
 - Look for a request for input

Flexibilities Made Permanent – Medicare Physician Fee Schedule (MPFS)

- **Subject to state scope of practice regulations**
- **Supervision of psychological and neuropsychological testing services**
 - Nurse Practitioners (NP)
 - Certified Nurse Specialists (CNSs)
 - Physician Assistants (PAs)
 - Certified nurse-midwives (CNMs)
- **Physical Therapists (PTs) and Occupational Therapists (OTs) may delegate maintenance therapy to assistants**

Flotsam & Jetsom

Miscellaneous Updates

Moratorium until 2024

G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)

- Not to be implemented – moratorium until 2024
- Removed from MPFS
- Still in OPPS Addendum B file

Most Favored Nation (MFN) Rule

- Currently under litigation
- Preliminary injunction halts implementation of the rule
- Unknown timeframe of enforcement



Questions?

References

- **American Medical Association (AMA)**

- <https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes>
- <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>
- <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>
- Hold

References, cont.

■ The Centers for Medicare & Medicaid Services (CMS)

- https://www.cms.gov/Medicare/Coding/ICD10/index?redirect=/ICD10/01_Overview.asp#TopOfPage
- <https://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/PodcastAndTranscripts>
- <https://www.cms.gov/covidvax-provider>
- <https://www.cms.gov/files/document/03092020-covid-19-faqs-508.pdf>
- <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c32.pdf>
- <https://www.govinfo.gov/content/pkg/FR-2020-12-29/pdf/2020-26819.pdf>
- <https://www.govinfo.gov/content/pkg/FR-2020-12-28/pdf/2020-26815.pdf>

A large, faint, light blue watermark of the Vitalware logo, which consists of a stylized 'W' inside a circle, is centered in the background.

Thank you!